Rinri Therapeutics Ltd. is a therapeutic discovery and development company working to develop advanced therapies for hearing loss, a global condition affecting millions with no approved therapies and poor patient outcomes. Rinri is leveraging its unique scientific expertise to develop regenerative cell therapies for hearing loss, capitalising on the power of pluripotent stem to restore hearing function by replacing the damaged sensory cells of the cochlea. Rinri has a portfolio approach to therapeutic development for hearing loss. Rinri’s lead product Rincell-1, a treatment for auditory neuropathy, is now in advanced preclinical development, with line of sight to rapidly establish clinical proof of concept. Rinri is supported by Boehringer Ingelheim Venture Fund and UCB Ventures, We Are Pioneer Group and The University of Sheffield.